Estepan Ian Michael 4

What Happened

• Estepan Ian Michael, Sarepta Therapeutics' Chief Operating Officer, was credited with 1,875 performance share units (PSUs) on Feb 25, 2026. This is an award/derivative transaction (code A) — not an open‑market buy or sale — and no cash price or immediate share transfer is reported. The PSUs were originally granted on March 1, 2024 and were determined to be earned based on achievement of specified milestones.

Key Details

• Transaction date: 2026-02-25 (reported on Form 4 filed 2026-02-27) — filing appears timely.
• Transaction type/code: Award/Grant (A); derivative security (PSUs).
• Shares/units acquired: 1,875 PSUs; price: N/A; no dollar value reported.
• Vesting: Earned PSUs will vest on March 1, 2026, contingent on continued service through that date (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The PSUs were part of a March 1, 2024 grant and were earned based on the Compensation Committee’s assessment of milestone achievement.

Context

• These are earned PSUs (derivative awards) and do not represent immediately tradable common shares until they vest and convert. Such awards reflect compensation and milestone-based payouts, not an open‑market buy or sell; they don’t by themselves indicate a trading view by the insider.